Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Melanoma 19Squamous Cell Carcinoma of Head and Neck 18Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Lung Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3

Interventions

Radiotherapy 11Brachytherapy 8fludarabine 5Radiation 5Magnetic Resonance Spectroscopy 5Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5Cyclophosphamide 5aldesleukin 4Surveys and Questionnaires 4Cisplatin 4fludarabine phosphate 3durvalumab 3Vaccines, Synthetic 3Radiosurgery 3Papillomavirus Vaccines 3Paclitaxel 3Methods 3Early Intervention, Educational 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tremelimumab 2entinostat 2aflibercept 2Vaccines 2Trastuzumab 2Topotecan 2Therapeutics 2Surgical Procedures, Operative 2Psychiatric Rehabilitation 2Platinum 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vaginal Neoplasms × tremelimumab × Clear all
NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
16 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

M.D. Anderson Cancer Center

Phase 1 Completed
20 enrolled
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡